NANJING, China, Nov. 2 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, announced today that it intends to release its 2009 third quarter results on Monday, November 16, 2009, before the market opens in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2009 third quarter results on the same day, at 8 a.m. ET (Monday, November 16, at 9 p.m. Beijing/Hong Kong time).
To access the conference call, please dial:
United States toll-free: +1.800.706.7741
International: +1.617.614.3471
North China toll-free: 10.800.152.1490
South China toll-free: 10.800.130.0399
China toll free / Netcom: 10.800.852.1490
Hong Kong: +852.3002.1672
Please ask to be connected to Q3 2009 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 32750293.
Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com .
Following the earnings conference call, an archive of the call will be available by dialing:
United States toll-free: +1.888.286.8010
International: +1.617.801.6888
The passcode for replay participants is: 77133325.The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells anti-infective medication, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
